- Compression Stockings Can Prevent Post Thrombotic Syndrome By : JB Ware
Post thrombotic syndrome is a long term complication of DVT that is experienced by 1 out of 3 patients. The symptoms include pain, swelling, cramping, numbness, tingling, and itching of the affected leg. The skin on the lower part of the leg may harden and darken. PTS symptoms may last for years. PTS may affect 50% of patients with DVT after 2 years. - Diagnosing Varicose Veins and Other Venous Disorders By : JB Ware
The diagnosis of venous disorders including varicose veins and chronic venous insufficiency requires an examination and tests performed by a qualified physician who specializes in venous diseases. These physicians are called Phlebologists. Patients should inquire about the physician’s qualifications as a Phlebologist. - Varicose Veins: More Than A Cosmetic Concern By : JB Ware
In addition to being ugly in appearance, varicose veins may have a serious impact on the general public’s quality of life. This is generally because vein disease affects the younger working population. Approximately one third of the population between the ages of 18 – 64 suffers from varicose veins that may be caused by chronic venous insufficiency (CVI). - Benefits of Wearing Medical Compression Stockings By : JB Ware
Wearing compression stocking on a regular basis may alleviate those tire aching legs people experience at the end of a long day. No need to come home and elevate those tired legs at the end of the day. The graduated compression action of stockings will softly massage the leg muscles all day while standing or sitting. This compression will prevent the venous blood in the legs from becoming sluggish and promote good blood flow from the legs back to the heart. - Amgen Responds To Reports About Use And Safety Of EPOGEN And Aranesp In CKD Anemia Therapy By : Hematology News
Amgen (NASDAQ:AMGN), today posted to its corporate web site documents intended to clarify Amgen's position on the use of EPOGEN(R) (Epoetin alfa) and Aranesp(R) (darbepoetin alfa) and to correct what the company believes are misleading and inaccurate news reports regarding the use of its drugs. Amgen's mission is to serve patients and the company is committed to ensuring the highest standards of patient safety. - New Biosensors From The Blood Of Llamas By : Hematology News
An unusual protein found in the blood of llamas has enabled scientists to develop a quick, simple method for making antibodies that could be used in a new generation of biosensors. - Megakaryocytes And Platelets Keep Blood Vessel Growth Under Control By : Hematology News
The growth of new blood vessels (a process known as angiogenesis) is essential during embryonic development, wound healing, and blood cell development in the bone marrow, but it also has a role in supporting tumor growth. - Megakaryocytes And Platelets Keep Blood Vessel Growth Under Control By : Hematology News
The growth of new blood vessels (a process known as angiogenesis) is essential during embryonic development, wound healing, and blood cell development in the bone marrow, but it also has a role in supporting tumor growth. - Genta Clinical Programs Featured In Presentations At Annual Meeting Of The American Society Of Hemat By : Hematology News
Genta Incorporated (Nasdaq: GNTA) announced that several presentations related to the Company's clinical programs will be featured at the annual meeting of the American Society of Hematology (ASH) in Orlando, FL during December 9-12, 2006. Programs involving - Sunesis Pharmaceuticals To Present Data On SNS-595 At American Society For Hematology Meeting By : Hematology News
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will present data from clinical and preclinical studies of SNS-595 in advanced leukemias at the upcoming American Society for Hematology - Avalon Pharmaceuticals To Present At The American Society Of Hematology 2006 Annual Meeting By : Hematology News
Avalon Pharmaceuticals, Inc. (Nasdaq and NYSE Arca: AVRX), announced that it will present pharmacodymanic endpoint data from a phase I study of AVN944 at the American Society of Hematology's 48th Annual Meeting to be held on December 9-12, in Orlando. AVN944 is the Company's lead product candidate for the treatment of hematologic malignancies. - FDA Advisory Committee To Consider Navy's Proposed 'Resus' Trauma Trial In Open Session On December By : Hematology News
iopure Corporation (Nasdaq: BPUR) announced today that the Food and Drug Administration's (FDA) Blood Products Advisory Committee will meet in open session on December 14, 2006 to discuss the Navy's proposed RESUS clinical trial of Biopure's investigational oxygen therapeutic Hemopure(R) - Emeka Okafor Launches African Initiative To Save Lives By : Hematology News
Emeka Okafor, 2005 NBA Rookie of the Year and Charlotte Bobcat star, announced Thursday, November 30th in Washington, DC, the launch of his new One Million African Lives Initiative ("Million Lives Initiative") in partnership with the Safe Blood for Africa Foundation (SBFA) - Cleveland Clinic Analysis Finds Patients With Drug-Eluting Stents Are At Increased Risk For Late Thr By : Hematology News
There is as much as a four- to five- fold increased relative risk for late thrombosis, or blood clot formation, in patients with drug-eluting stents compared to those with bare-metal stents, according to a Cleveland Clinic-led meta-analysis published in the December issue of the American Journal of Medicine. - Blood Donors And Drives Needed In Decembe By : Hematology News
New York Blood Center is predicting a severe blood shortage in December that will require blood rationing to area hospitals and patients if blood supply levels do not improve, blood center management reported today. - Too Many Healthcare Workers Exposed To Bloodborne Viruses, UK By : Hematology News
A new report from the Health Protection Agency shows that healthcare workers are still being exposed to bloodborne virus infections, even though such exposures are largely preventable. According to data collected by the Agency, eleven healthcare workers were infected with hepatitis C via needle stick injuries in the last eight years; two of these incidents were reported in the last 12 months. - Blood Transfusions Should Be Used In Moderation For Acute Coronary Syndrome By : Hematology News
In a study of more than 44,000 patients being treated for a possible heart attack, cardiologists at the Duke Clinical Research Institute found that while transfusions were associated with a benefit in some patients, they were associated with harm in others. - Is Blood Coagulating Drug Dangerous For Troops Or A Life Saver? By : Hematology News
Recombinant Activated Factor VII, a blood coagulating drug, is considered a medical breakthrough for Army doctors - they say it gives them an effective way to control fatal bleeding of front line wounded patients. - Novel Drug-Antidote Combination Shown Safe In Humans By : Hematology News
A new combination of a potent anticoagulant and an antidote that stops its action, has proved to be safe in its first clinical trial in humans, according to the team conducting the trial. - FDA Grants Priority Review For Soliris(TM) (eculizumab) BLA For Treatment Of Paroxysmal Nocturnal By : Hematology News
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Biologics License Application (BLA) for Soliris(TM) (eculizumab) for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). - Researchers Develop Novel Method For Treatment Of Sickle Cell Disease By : Hematology News
Virginia Commonwealth University researchers have developed a unique anti-sickling agent that may one day be effective in treating sickle cell disease, a painful and debilitating genetic blood disorder that affects approximately 80,000 Americans. - Instrumentation Laboratory Receives FDA Clearance For Homocysteine Assay By : Hematology News
Instrumentation Laboratory (IL) today announced that the U.S. Food and Drug Administration (FDA) cleared the 510(k) for their HemosIL(TM) Homocysteine assay. This product is an automated, latex-enhanced immunoassay for the quantitative determination of total L-homocysteine (Hcy) in human citrated plasma on IL Coagulation Systems. Elevated levels of Hcy are associated with a variety of pathologies, particularly those which increase risk of cardiovascular disease and venous thromboembolism. - Cell Adhesion Strategies Revealed By : Hematology News
With the aid of complex computer simulations, scientists at the Max Planck Institute of Colloids and Interfaces in Potsdam and at the University of Heidelberg have discovered how the shape and distribution of certain sticky areas on the cell affect its adhesion in blood vessels. - Biopure's Phase II Trauma Trial Of Hemopure(R) In South Africa Continues Following Independent Panel By : Hematology News
Biopure Corporation (Nasdaq: BPUR) announced today that the independent Data and Safety Monitoring Board (DSMB) for the company's Phase II clinical trial of Hemopure(R) [hemoglobin glutamer - 250 (bovine)] in trauma patients has completed its first scheduled interim analysis of blinded study data and recommended that the trial continue without modification. - Keeping Cancer At Bay: Long-term Therapy In The Fight Against Multiple Myeloma By : Hematology News
There is no known cure for multiple myeloma, so its diagnosis means high-dose chemotherapy followed by repeated treatments with each relapse of the cancer - a watch and wait approach. A new approach of providing patients with continuous therapy to keep the cancer at bay was explored by a team of international researchers from France, Switzerland, and Belgium; their findings will be published in the November 15, 2006, issue of Blood, the official journal of the American Society of Hematology - New Trial For First Renal Anaemia Treatment Produced In Human Cell Lines Launched By Shire By : Hematology News
Shire has announced the start of a new Phase IIIb clinical trial to evaluate two new dosing schedules of DYNEPO® (epoetin delta), the first commercial erythropoiesis-stimulating agent produced in a human cell line. DYNEPO is used in the treatment of anaemia in patients with chronic kidney disease (CKD[*]). Anaemia becomes more common and severe as a patient's kidney function declines.(1) - Ulcer Bacteria H. Pylori Present In Blood Vessels By : Hematology News
A research group from the Uniformed Services University of the Health Sciences (USU), in collaboration with European researchers, demonstrated that the peptic ulcer bacterium Helicobacter pylori (H. pylori) can reach the blood circulation. Thus, the bacterium can disseminate in the body and may cause other chronic inflammatory conditions of unknown origin, such as atherosclerosis and rheumatoid arthritis. - Ulcer Bacteria H. Pylori Present In Blood Vessels By : Hematology News
A research group from the Uniformed Services University of the Health Sciences (USU), in collaboration with European researchers, demonstrated that the peptic ulcer bacterium Helicobacter pylori (H. pylori) can reach the blood circulation. Thus, the bacterium can disseminate in the body and may cause other chronic inflammatory conditions of unknown origin, such as atherosclerosis and rheumatoid arthritis. - Novel Laboratory Model Reveals Clues To How Blood Starts Clotting By : Hematology News
Researchers at the University of Chicago have crafted a simple model for predicting when and where hemostasis -- the technical term for blood clotting -- will occur. The microfluidic system that they created focuses on the interactions between blood and surfaces patterned to trigger blood clotting. It allows the researchers to separately monitor clotting in both blood plasma and a chemical model. - MIT Reveals Inner Lives Of Red Blood Cells By : Hematology News
For the first time, researchers at MIT can see every vibration of a cell membrane, using a technique that could one day allow scientists to create three-dimensional images of the inner workings of living cells. - Immunicon to Present the New EasyCount™ IMS System at the 2006 Annual Meeting of the American By : Health News
Immunicon Corporation (NASDAQ-GM:IMMC) will make an oral presentation at the annual meeting of the American Association of Blood Banks at 4:30 p.m. ET on October 23, 2006, at the Miami Beach Convention Center in Miami Beach, Florida. Dania Yaskanin, Ph.D., Senior Scientist of Immunicon, will present, “Enumeration of Residual Leukocytes in Leukodepleted Blood Products with a Simple Fluorescence Imaging System.” - Protein Important In Blood Clotting May Also Play A Role In Fertility By : Hematology News
A protein known to play a role in blood clotting and other cell functions is also critical for proper sperm formation in mice, according to researchers from the University of North Carolina at Chapel Hill School of Medicine. - Study Shows Nearly One In Five People Plan To Donate Blood In The Next Year By : Hematology News
Results from an America's Blood Centers' study presented today at the AABB Annual Meeting show that nearly one in five people in the United States plans to donate blood in the next year. "Donating the most needed component(s)," such as red blood cells and platelets, was the primary reason mentioned by more than 50 percent of respondents who intended to make their next donation on an automated collection system. - Eli Lilly Accused Of Influencing Sepsis Guidelines By : Hematology News
Guidelines, which are supposed to be independent and scientific, have been influenced by a pharmaceutical giant, Eli Lilly, say US government doctors. They say that the company influenced treatment guidelines for sepsis, a blood infection which is often fatal. - HRSA To Allocate $14M To Public Umbilical Cord Blood Banks By : Hematology News
HHS' Health Resources and Services Administration plans to allocate $14 million to public umbilical cord blood banks nationwide in an effort to increase the supply of cord blood from 50,000 to 150,000 units, the AP/Washington Post reports. HRSA also recently awarded about $10 million in contracts to coordinate cord donations and monitor the outcome of transplants (Freking, AP/Washington Post, 10/16). - Abaxis Announces CLIA Waived Status By : Hematology News
Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that the U.S. Food and Drug Administration (FDA) has granted waived status under CLIA regulations for six additional analytes -- Albumin (ALB), Alkaline Phosphatase (ALP), Amylase (AMY), Gamma Glutamyltransferase (GGT), Total Bilirubin (Tbili), and Total Protein (TP) -- when used in conjunction with the Piccolo point-of-care analyzer for the medical market. - NovoSeven(R) Becomes First And Only Recombinant Therapy For Treatment Of Rare, Life-Threatening By : Hematology News
The United States Food and Drug Administration (FDA) has approved a new indication for NovoSeven(R) Coagulation Factor VIIa (Recombinant), making it the first and only recombinant therapy approved for the treatment of acquired hemophilia, a rare and potentially fatal bleeding disorder. As a recombinant therapy, NovoSeven(R) is not plasma-derived and poses no risk of human viral transmission through its use. - Daxor Corporation Announces Queens Medical Center of Honolulu, HI Acquires Second Blood Volume By : Health News
Daxor Corporation (AMEX:DXR), a medical instrumentation and biotechnology company, today announced receipt of a signed trial agreement from the Queen's Medical Center in Honolulu, Hawaii for its second Blood Volume Analyzer. Queen’s Medical Center, which purchased its first BVA-100 following a trial agreement, utilized blood volume measurements for various clinical applications. - NHS Should Not Encourage Commercial Blood Banking Of Umbilical Cord Blood, UK By : Hematology News
NHS maternity units should not encourage commercial banking of umbilical cord blood, argues a senior doctor in this week's BMJ. - Using Chemistry To Predict The Dynamics Of Clotting In Human Blood By : Hematology News
University of Chicago chemists have demonstrated for the first time how to use a simple laboratory model consisting of only a few chemical reactions to predict when and where blood clotting will occur. The scientists used microfluidics, a technique that allowed them to probe blood clotting on surfaces that mimic vascular damage on the micron scale, a unit of measurement much narrower than the diameter of a human hair. - Bayer Appoints Independent Investigator To Review Trasylol(R) Study Issues By : Hematology News
Bayer announced today that it has appointed independent counsel to review the company's actions in regards to disclosure of preliminary results from an observational study on Trasylol(R) to the U.S. Food and Drug Administration. - Safe Blood For Africa Conducts West/Central African Donor Recruitment Workshop By : Hematology News
An International Blood Safety Workshop on the crucial role of "Developing Voluntary Blood Donor Programs" was held in Accra, Ghana, October 2 to 13, 2006 for 16 West and Central African countries. - NHS Should Not Encourage Commercial Blood Banking By : Hematology News
NHS maternity units should not encourage commercial banking of umbilical cord blood, argues a senior doctor in this week's BMJ. - MIT Material Stops Bleeding In Seconds By : Hematology News
MIT and Hong Kong University researchers have shown that some simple biodegradable liquids can stop bleeding in wounded rodents within seconds, a development that could significantly impact medicine. - Data Presented On The Impact Of Rapid Testing With PNA FISH(TM) On Patient Care By : Hematology News
In conjunction with the recently concluded 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, Dr. Graeme Forrest, M.D., Infectious Diseases Physician and Director of Antimicrobial Utilization at the University of Maryland Medical Center (UMMC), presented data on the impact that rapid testing with PNA FISH(TM) has on patient care. - Bonfils Blood Center Chooses Data393 as Managed Infrastructure Provider By : Health News
Data393, a leading Colorado managed IT infrastructure provider, announced today that it has signed an agreement to provide Bonfils Blood Center in Colorado with Data393’s Metro Area Ethernet connectivity and colocation services through Data393’s facility in the Denver Tech Center. - Blood Cells Linked To Heart Attacks, Stroke And Other Inflammatory Diseases By : Hematology News
Two human blood cells that help fight blood loss, infection, and inflammation are responsible as well for starting a series of molecular events that results in overproduction of Cox-2, an enzyme involved in heart attack, stroke, atherosclerosis, and other inflammatory diseases. - Automated Technique Accurately Measures Platelet Counts In "Platelet Gel" Products By : Hematology News
A special blood concentrate known as platelet-rich plasma (PRP) can promote healing in a wide range of medical and surgical situations, but research has been limited by the lack of a universally accepted approach to measuring the platelet concentrations contained in PRP. A study in the September/October 2005 issue of The Journal of Craniofacial Surgery presents an accurate approach to measuring platelet counts in PRP preparations, using standard hematology equipment. - CXCL12 Blocks The Way To The Bone Marrow By : Hematology News
Hematopoietic stem cells (HSCs) are the cells that give rise to all the different cell types in the blood and HSC transplantation is used to treat a number of blood disorders, including some cancers of the blood. These cells are mostly found in the bone marrow, although they can also be detected in umbilical cord blood, the placenta, and the fetal liver. The processes that control the recruitment and retention of HSCs in the bone marrow are not well understood, particularly during development. - Gen-Probe Receives FDA License For PROCLEIX(R) ULTRIO(R) Assay By : Hematology News
Gen-Probe (Nasdaq: GPRO) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for the PROCLEIX(R) ULTRIO(R) Assay to run on the enhanced Semi-Automated PROCLEIX(R) System (eSAS). - Contract Supports Vital Work Of The Center For International Blood And Marrow Transplant Research By : Hematology News
The Medical College of Wisconsin, Milwaukee, announced that the Center for International Blood and Marrow Transplant Research (CIBMTR) has been awarded the Stem Cell Therapeutic Outcomes Database contract by the U.S. Health Resources and Services Administration (HRSA). - FDA Statement Regarding New Trasylol Data By : Hematology News
Since January, 2006, the Food and Drug Administration (FDA) has been conducting a safety review of Trasylol (aprotinin injection). The review was triggered by the results of two published research studies: one that reported an increase in the chance of kidney failure, heart attack and stroke in patients treated with Trasylol compared to those treated with other similar drugs, and the other that reported an increase in kidney dysfunction compared to another drug. - Management Of Deep Vein Thrombosis With Unfractionated Heparin Equally Safe As Low-Molecular Weight By : Hematology News
Contrary to oral warfarin therapy, the use of subcutaneous low-molecular weight heparin (LMWH) has the advantage of stable dosing without the need of prothrombin time monitoring. Few randomized studies have compared the efficacy of LMWH with the least costly unfractionated heparin for the treatment of deep vein thrombosis (DVT). In the United States, 6 days of LMWH therapy for an 80 kg patient is estimated to cost $712, compared with $37 of unfractionated heparin. - “Safe” Blood Levels Need Redefining By : Hematology News
Blood lead levels currently considered safe by the U.S. government have been found to be associated with increased risk of death from many causes, including heart disease and stroke, according to a report in Circulation: Journal of the American Heart Association. - Blood Transfusion-Transmitted Infections: A Global Perspective By : Hematology News
Thanks to the many blood-safety interventions introduced since 1984, the overall risk for most transfusion-transmitted infections has become exceedingly small. - Key To Production Of Heme In Hemoglobin Is ABCB6 By : Hematology News
Investigators at St. Jude Children's Research Hospital have discovered that a protein called ABCB6 plays a central role in production of a molecule that is key to the ability of red blood cells to carry oxygen, of liver cells to break down toxins, and of cells to extract energy from nutrients. - Verax Biomedical Initiates Two External Clinical Trials By : Hematology News
Verax Biomedical, Inc., a leading developer of rapid tests for detecting bacterial contaminants found in blood cells and tissue, has initiated an external clinical trial of its Platelet PGD(R) Test at University Hospitals Case Medical Center and at the Cleveland Clinic. The trial will generate data for filing a 510(k) pre-market notification with the Food & Drug Administration (FDA) for the QC testing of platelets for the presence of bacteria. - ABCB6 Is Key To Production Of Heme In Hemoglobin By : Hematology News
Investigators at St. Jude Children's Research Hospital have discovered that a protein called ABCB6 plays a central role in production of a molecule that is key to the ability of red blood cells to carry oxygen, of liver cells to break down toxins, and of cells to extract energy from nutrients. - BioE Executives to Present at 35th Annual International Society for Experimental Hematology Meeting By : Health News
BioE®, Inc., a biomedical company providing human umbilical cord blood stem cells as enabling, high-quality cellular tools for drug discovery and therapeutic research, announced today its executives will participate in and present at the 35th Annual International Society for Experimental Hematology (ISEH) meeting later this week at the Hyatt Regency in downtown Minneapolis. BioE also announced it has launched a new, enhanced corporate Web site at www.bioe.com. - Potential Effective Therapy For PNH, Improving Anaemia And Quality Of Life In Patients By : Hematology News
A study led by Dr Peter Hillmen of the Leeds Teaching Hospitals NHS Trust, relating to an uncommon and severe haemolytic anaemia known as paroxysmal nocturnal haemoglobinuria (PNH), was published in the current issue of The New England Journal of Medicine. In the Phase III efficacy study, TRIUMPH, 87 patients were treated at 34 sites in the U.S., Canada, Europe, and Australia. The data showed clinically significant improvements in anaemia and the quality of life for patients with PNH. - State Of Sickle Cell Disease Is Focus Of National Meeting Taking Place In Dallas By : Hematology News
Patient advocates, researchers, clinicians, policy makers, and minority health leaders will address the state of Sickle Cell Disease awareness and treatment in the U.S.A when the Sickle Cell Disease Association of America (SCDAA) holds it 34th annual meeting September 27-30 at the Hyatt Regency Dallas at Reunion in Dallas, Texas. - Roadmap To Integrin Activation Created By UCSD Researchers By : Hematology News
Calling it an important technical advance in the study of the complex receptors and pathways of the body's cellular system, researchers at the University of California, San Diego (UCSD) School of Medicine have reconstructed the signaling pathways that impact activation of a receptor that is critical to the control of bleeding and to the thrombosis that occurs in heart attacks and strokes. - Medtronic Micro-Driver Coronary Stent Approved in Japan By : Health News
Medtronic, Inc. (NYSE:MDT) today announced that it has received Japanese regulatory approval and will begin sales of the Micro-Driver coronary stent system, the first Cobalt-Chromium stent designed for small blood vessels requiring stents smaller than 3 millimeters in diameter. Micro-Driver is an extension of the popular Medtronic Driver(R) stent, the most implanted bare metal stent in Japan for patients with larger blood vessels. - Exjade, For Patients With Transfusional Iron Overload, Gains European Union Approval By : Hematology News
The European Commission (EC) has granted approval for Exjade (deferasirox) as a new treatment to help patients with transfusional iron overload in all 25 member states of the European Union (EU). - DH And Customs Investigating A Case Of A Boy Developing Blueness After Playing Toys By : Hematology News
The Department of Health and the Customs and Excise Department were investigating a case involving a 12-month-old boy who developed blueness on his lips after playing stamped ink toys. - Daxor Announces Christiana Care Health System of Newark, DE Purchases Blood Volume Analyzer BVA-100 By : Health News
Daxor Corporation (AMEX:DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed purchase agreement from Christiana Care Health System of Newark, Delaware. - Cerus Corporation Announces Significant Presence at International Blood Safety Conference By : Health News
Cerus Corporation (NASDAQ:CERS) today announced that the company's INTERCEPT Blood System will be featured at the annual congress of the International Society of Blood Transfusion (ISBT) being held in Cape Town, South Africa, from September 2nd through 7th. - Stanford Blood Center Testing All Donated Blood for West Nile Virus By : Health News
As part of its planned precautionary efforts, the Stanford Blood Center is testing all donated blood for West Nile Virus in response to 88 cases of the infection being reported in California, including one in Santa Clara County and three in Contra Costa County. - Patient Treatment Completed in Synthetic Blood Traumatic Brain Injury Trial By : Health News
Synthetic Blood International, Inc. (OTCBB:SYBD) today announced the completion of treatment in the Company's Phase IIa open-label, proof-of-concept Oxycyte(TM) study in traumatic brain injury. Oxycyte administration increased oxygen tension over baseline in all eight evaluable trial patients. The Company expects to announce results of preliminary data analysis from this trial in the 4th quarter. - Measures To Check Sickle-cell Disease In Africa Proposed By Dr Sambo By : Hematology News
The World Health Organization (WHO) Regional Director for Africa, Dr Luis Sambo, has proposed measures to check sickle-cell disease. The prevalence of sickle-cell trait ranges between 10% and 40% of the population in some parts of the African Region. - Drug Fights Multiple Myeloma By Putting "Brakes" On Cell Proliferation By : Hematology News
An experimental drug targeted to a cancer-causing mechanism within the cell may be a powerful weapon against deadly multiple myeloma. - Less Expensive Anti-clotting Medication Appears As Safe And Effective As More Expensive Treatment By : Hematology News
Subcutaneous (beneath the skin) injection of the original and less expensive form of the anticoagulant medication heparin is as effective and safe as subcutaneous administration of the newer and more expensive low-molecular-weight heparin for treatment of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs), according to a study in the August 23-30 issue of JAMA. - Blood Clots Can Be Treated By Injections At Home By : Hematology News
Treatment of blood clots in the deep veins of the legs or the lungs with an older, less expensive form of the anticoagulant medication heparin can be just as safe and effective as similar treatment with a newer and more expensive heparin, according to a study led by Clive Kearon, professor of medicine at McMaster University, published in the August issue of JAMA (The Journal of the American Medical Association). - Inflammation And Risk Of Venous Thrombosis By : Hematology News
The results from a large population-based study in Norway, published in the international open-access medical journal PLoS Medicine, show that altered levels of inflammatory markers are more likely to be a result rather than a cause of venous thrombosis, although short-term effects of transiently elevated levels cannot be ruled out. - CVRx Receives Innovator of the Year Award; Company Recognized for Developing Implantable By : Health News
VRx Inc., a private company that has developed an implantable medical device to treat high blood pressure, announced today that Dr. Robert Kieval, as president and chief executive officer, received a Finance and Commerce Innovator of the Year 2006 award. - Link Between Autism And Abnormal Blood-Vessel Function, Oxidative Stress By : Autism News
Researchers at the University of Pennsylvania School of Medicine discovered that children with autism showed signs of abnormal blood-vessel function and damaging levels of oxidative stress compared to healthy children. The children with autism possessed levels of biochemicals that indicate the presence of constricted blood vessels via the endothelium (the cells that line vessels) with a higher tendency to form clots (through cells called platelets). - Abnormal Blood Test Results Associated With Acne Medication By : Hematology News
Elevated cholesterol levels and liver enzyme levels appear to be more common than previously thought among patients taking the acne medication isoretinoin, including those who had normal blood test results before beginning therapy, according to a report in the August issue of Archives of Dermatology, one of the JAMA/Archives journals. - Several Types Of Travel Increase Risk Of Venous Thrombosis By : Hematology News
Traveling for more than 4 hours by air, car, bus or train is associated with an increased risk of venous thrombosis. In a large study (the MEGA study) of nearly 2000 people with a first thrombosis in the Netherlands, Dr Suzanne Cannegieter and colleagues from the Leiden University Medical Center looked at the risk factors for thrombosis compared with their partners, who did not have thrombosis. - Non-Invasive Monitoring Systems, Inc. (NIMS) Announces Grant of Patent on Non-Invasive Means By : Health News
Gary MacLeod, Chief Executive Officer, Non-Invasive Monitoring Systems, Inc. (OTCBB:NIMU) announced that the US Patent Office issued Patent 7,090,648 on August 15, 2006 entitled, "External addition of pulses to fluid channels of body to release or suppress endothelial mediators and to determine effectiveness of such intervention." - The New England Journal of Medicine Publishes Results of Cubist's Landmark Study of Staphylococcus By : Health News
Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced that the New England Journal of Medicine (NEJM) has published results from the company's landmark Phase 3 study of CUBICIN(R) (daptomycin for injection) at 6 mg/kg as monotherapy vs. dual therapy standard of care for the treatment of patients with Staphylococcus aureus (S. aureus) blood stream infections (bacteremia) and infective endocarditis (infection of the heart valves). - Introduction Of New Advate Convenience Features For Plasma-albumin-free Haemophilia A Therapy By : Hematology News
COMPTON, England - Baxter Healthcare Ltd announced today the introduction of BAXJECT II, an innovative needle-less reconstitution device and an improved packaging design for its plasma-albumin-free haemophilia A therapy ADVATE. Introduction of these two new convenience features has just started and patients will begin to receive them in the coming weeks. - Advate's Safety Profile Confirmed For Haemophilia Therapy By : Hematology News
The MHRA has announced the removal of Advate's (Octocog Alfa Recombinant Coagulation Factor VIII) black triangle symbol, confirming its risk/benefit balance. The move marks the end of a period of detailed surveillance following the UK launch of Advate, the first and only haemophilia therapy without blood-based additives used for the prevention and control of bleeding episodes in people with haemophilia A. - Scientist Discovers Crucial Part Of Blood-Clotting Process By : Hematology News
researcher at The University of Texas Health Center at Tyler has discovered how a small but crucial part of the blood-clotting process works. Once the process is thoroughly understood, synthetic chemicals can be designed to regulate it, thus preventing excessive bleeding or blood clotting. The findings of Pierre Neuenschwander, Ph.D., and his team are published in the Aug. 11, 2006, edition of the Journal of Biological Chemistryn. - Are You A Little Low? Failure To Match Energy Intake With Requirements By : Medical News
As many as one third of women experience symptoms which they believe are caused by low blood glucose (sugar), according to a recent survey conducted in Nottinghamshire (1). The symptoms of such low blood glucose (or hypoglycaemia, as it is medically termed), include: irritability; faintness; tremor; hunger and anxiety. However, it is not known whether such women experience true (biochemically defined) hypoglycaemia or whether their symptoms are caused by some other factor. - Mississippi Blood Services Improves Product Integrity And Delivery With RFID From Texas Instruments By : Medical News
With a short shelf life and cold storage conditions required for its products, Mississippi Blood Services recently completed its first trial using radio frequency identification (RFID) from Texas Instruments Incorporated (NYSE: TXN) (TI) and AARFID to streamline inventory management, strengthen safety procedures and improve hospital delivery. - CuraGen And TopoTarget Announce Initiation Of NCI-sponsored Phase I Clinical Trial Of PXD101 By : Medical News
CuraGen Corporation (Nasdaq: CRGN) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase I clinical trial evaluating the safety and tolerability of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with azacitidine for the treatment of advanced hematologic malignancies. This trial is being sponsored by the National Cancer Institute (NCI) under a Clinical Trials Agreement with CuraGen for the development of PXD - Medical City Is First North Texas Donor Site For Texas Cord Blood Bank By : Medical News
On Wednesday, August 9, Medical City will become the Texas Cord Blood Bank's first donor site in North Texas -- and the fourth in the state. The Texas Cord Blood Bank, a division of the South Texas Blood & Tissue Center, is a non-profit program established by the Texas legislature in 2001 to collect umbilical cord blood that can benefit patients suffering from a number of potentially fatal diseases. - Einstein's Dr. E. Richard Stanley Receives 2006 E. Donnall Thomas Prize By : Medical News
E. Richard Stanley, Ph.D., professor and chair of developmental and molecular biology at Albert Einstein College of Medicine of Yeshiva University has been selected to receive the 2006 E. Donnall Thomas Prize, presented annually by the American Society of Hematology. - Blood Clot Fibers More Elastic Than Spider's Web By : Medical News
The tiny fibers that comprise blood clots show extraordinary elasticity, on average stretching to almost three times their length while still retaining their ability to go back to their normal shape and expanding to more than four times their length before breaking, according to findings published in the journal Science this week by researchers at Wake Forest University. - Men More At Risk Of Recurrent Blood Clots Than Women By : Medical News
Men have a 50% higher relative risk of suffering from recurrent blood clots after a first episode than women, according to an article in The Lancet. The baseline frequency of recurrent blood clots is 25% after five years. - ACE-ing The Test Of Blood Pressure Regulation By : Medical News
Angiotensin converting enzyme 2 (ACE2) is expressed at its highest levels in the kidney and heart, suggesting a potential role in the regulation of the cardiovascular system. - Test Helps Identify Patients At Low Risk For Recurring Blood Clots By : Medical News
A test that measures the generation of a certain protein involved with blood clotting can help determine whether patients who have experienced a venous blood clot are at low risk of developing another blood clot, and thus avoiding anticoagulant treatment and its possible side effects, according to a study in the July 26 issue of JAMA. - FDA Clears Body Fluids Analysis Application For Sysmex XT-Series By : Medical News
Sysmex America, Inc. announced today that the Body Fluid application on the Sysmex XT-2000i(TM) and Sysmex XT-1800 (TM) Automated Hematology Analyzers has been cleared by the United States Food and Drug Administration (FDA) for the analysis of cerebrospinal fluid (CSF), serous and synovial fluids, said John Kershaw, President, Sysmex America, Inc. The XT-series analyzer is an instrument designed for mid volume laboratories.
|
